Return to Main Site 617-919-3019
401 Park Drive, 7th Floor East, Boston, MA 02215

TIDO Technology Search



Invention Type

Diagnostic/Prognostic
Information Technology/Software
Medical Device
Other
Research Tool
Therapeutics

Research Area

Allergy/Respiratory/Pulmonary Disease
Anesthesia
Cardiovascular/Cardiology
Degenerative Disease
Dermatology
Endocrinology
Gastrointestinal/Nutrition
Genetic Disease
Health Care Management
Immunology
Infectious Disease
Inflammation
Internal Medicine
Metabolic Disease
Musculoskeletal
Neonatology/Pediatric
Neurology/Neuroscience
Oncology/Hematology
Ophthalmology
Otolaryngology/Audiology
Pain
Pathology
Personalized Medicine
Psychiatric Disease
Radiology
Regenerative Medicine
Reproduction/Ob-Gyn
Stem Cell
Surgery/Wound Healing
Urology
CMCC 1594

Novel Treatment for Polycystic Kidney Disease (PKD)

Inventors: Jordan Kreidberg, Shan Qin

Invention Types: Therapeutics

Research Areas: Urology

Keywords: Animal Model (mouse), New Indication/Use, Small Molecule/Drug

For More Information Contact:  Caron, Connie

 

Invention Description:

Polycystic Kidney Disease (PKD) is the most common life-threatening genetic disease, affecting 600,000 Americans and 12.5 million people worldwide. PKD causes fluid-filled cysts to grow on the kidneys. Progressive accumulation of renal cysts causes grossly enlarged kidneys, and leads to renal failure in the majority of patients. About 50% of patients will require dialysis or a kidney transplant by the time they reach their 60s. Many individuals with PKD experience end stage renal disease as early as their 20s. Drs. Kreidberg and Qin have shown that inhibiting a well known membrane receptor, c-Met, reduces the number and size of cysts in a murine embryonic kidney organ culture model of PKD.

Applications:

The discovery of Drs. Kreidberg and Qin describes a new role for c-Met in the pathogenesis of PKD and indicates that it may be a therapeutic target for this disease. These findings further suggest that c-Met inhibitors may represent a new strategy to treat PKD.

Competitive Advantages:

There is currently no known treatment or cure for PKD. Dialysis and transplantation are the options for patients who develop kidney failure. Pain and hypertension medicines, and ultimately laparoscopic surgery to eliminate existing cysts, are often used to alleviate the symptoms associated with PKD. Several inhibitors of c-Met are currently in development as anti-cancer agents. The discovery herein reveals a potential new use for these inhibitors for treatment of PKD.

Business Opportunity:

Exclusive License and Sponsored Research

Key Publications: Qin S, et al. Failure to ubiquitinate c-Met leads to hyperactivation of mTOR signaling in a mouse model of autosomal dominant polycystic kidney disease. J Clin Invest. 2010 Oct;120(10):3617-28.

Qin S, et al. c-Met and NF-kB-dependent overexpression of Wnt7a and -7b and Pax2 promotes cystogenesis in polycystic kidney disease. J Am Soc Nephrol. 2012 Aug;23(8):1309-18.

IPStatus: Pat. Pend.